Boston Life Sciences (Hopkinton, Massachusetts) reported that its proposed name change to Alseres Pharmaceuticals was approved by its stockholders at its annual meeting of stockholders. Alseres’ common shares will begin trading under a new NASDAQ Capital Market symbol ALSE. The new CUSIP number for ALSE common stock is 021152103.

“We have made excellent progress transforming the company from a life sciences company into a biopharmaceutical company with late stage product candidates in clinical development for Central Nervous System disorders,” said Peter Savas, Alseres chairman and CEO. “Our new name, Alseres Pharmaceuticals, is intended to support our evolving strategic vision. Alseres is derived from a Latin term meaning ‘to grow together, to take root, to become established’ and we believe provides an image for our growing pipeline, scientific expertise, management and culture.” Alseres Pharmaceuticals makes diagnostic and therapeutic products for central nervous system (CNS) disorders.